AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28059912 — intervention group
Group type: COMPARATOR
Intervention: Excision with open healing
Number of subjects: 140
Study 26502966 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-alpha hydroxy progesterone
Number of subjects: 60
Study 26502966 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide
Number of subjects: 60
Study 23506464 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Normative Feedback (PNF)
Number of subjects: 365
Study 23506464 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective Behavioral Strategies Feedback (PBSF)
Number of subjects: 365
Study 23506464 — intervention group
Group type: COMPARATOR
Intervention: Alcohol Education (AE)
Number of subjects: 365
Study 21298522 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port transumbilical total laparoscopic hysterectomy (SPLS-TLH)
Number of subjects: 68
Study 21298522 — intervention group
Group type: COMPARATOR
Intervention: Four-port total laparoscopic hysterectomy (TLH)
Number of subjects: 68
Study 19141125 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab (Simulect) administration
Number of subjects: 0
Study 19141125 — intervention group
Group type: COMPARATOR
Intervention: Control group (recipients without basiliximab injection)
Number of subjects: 0
Study 18184535 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐MPH bimodal release formulation (20 mg)
Number of subjects: 25
Study 18184535 — intervention group
Group type: COMPARATOR
Intervention: d‐MPH immediate release formulation (two 10 mg doses given 4 h apart)
Number of subjects: 25
Study 18184535 — intervention group
Group type: EXPERIMENTAL
Intervention: d,l‐MPH bimodal release formulation (40 mg)
Number of subjects: 25
Study 15017215 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 0
Study 15017215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11573581 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil/propofol (n=10)
Number of subjects: 20
Study 11573581 — intervention group
Group type: COMPARATOR
Intervention: sufentanil/propofol (n=10)
Number of subjects: 20
Study 9610998 — intervention group
Group type: EXPERIMENTAL
Intervention: Ring block
Number of subjects: 40
Study 9610998 — intervention group
Group type: COMPARATOR
Intervention: No anesthesia
Number of subjects: 40
Study 7993707 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiphospholipid antibodies (aPL)
Number of subjects: 0
Study 7993707 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic modalities
Number of subjects: 0
Study 3251497 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg of sustained release PPA
Number of subjects: 14
Study 3251497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30698069 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment (radiotherapy for endometrial cancer)
Number of subjects: 395
Study 30698069 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment (chemotherapy for ovarian cancer)
Number of subjects: 395
Study 30698069 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy or early-stage disease
Number of subjects: 395
Study 30698069 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment
Number of subjects: 395
Study 30698069 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical characteristics (comorbidities, treatment, tumor stage)
Number of subjects: 395
Study 30698069 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociodemographic characteristics (socioeconomic status)
Number of subjects: 395
Study 30698069 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive and social functioning
Number of subjects: 395
Study 28661205 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemorrhagic shock induced using Wigger’s shock model, followed by blood reinfusion.
Number of subjects: 0
Study 28661205 — intervention group
Group type: COMPARATOR
Intervention: Control animals (not specified how they were treated).
Number of subjects: 0
Study 26429700 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment with dihydroartemisinin‐piperaquine
Number of subjects: 1546
Study 26429700 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent screening and treatment with dihydroartemisinin‐piperaquine
Number of subjects: 1546
Study 26429700 — intervention group
Group type: COMPARATOR
Intervention: Intermittent preventive treatment with sulfadoxine‐pyrimethamine
Number of subjects: 1546
Study 23168523 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification (ILS)
Number of subjects: 706
Study 23168523 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg BID)
Number of subjects: 706
Study 23168523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 706
Study 21148051 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin + AICAR (67 mg·kg(‐1))
Number of subjects: 10
Study 21148051 — intervention group
Group type: COMPARATOR
Intervention: Insulin + placebo (saline)
Number of subjects: 10
Study 18251611 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing + flossing + Listerine (N = 25)
Number of subjects: 50
Study 18251611 — intervention group
Group type: COMPARATOR
Intervention: Brushing + flossing (N = 25)
Number of subjects: 50
Study 16904415 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (20 microg of ethinylestradiol (EE)/100 microg of levonorgestrel)
Number of subjects: 280
Study 16904415 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (15 microg of EE/60 microg of gestodene)
Number of subjects: 280
Study 16904415 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal ring (15 microg of EE/120 microg of etonogestrel)
Number of subjects: 280
Study 16904415 — intervention group
Group type: COMPARATOR
Intervention: All groups (combined oral contraceptives and vaginal ring)
Number of subjects: 280
Study 12829654 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (heart rate‐controlled endurance training twice a week and supervised muscle strength training twice a week for 12 months)
Number of subjects: 50
Study 12829654 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment only (Control group)
Number of subjects: 50
Study 10661003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 0
Study 10661003 — intervention group
Group type: COMPARATOR
Intervention: Imaginal exposure
Number of subjects: 0
Study 8965102 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific training for neglect
Number of subjects: 3
Study 8965102 — intervention group
Group type: COMPARATOR
Intervention: General cognitive intervention
Number of subjects: 3
Study 8965102 — intervention group
Group type: EXPERIMENTAL
Intervention: Neglect training (after switching from general cognitive intervention)
Number of subjects: 3
Study 1701817 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonococcal pilus vaccine
Number of subjects: 20
Study 1701817 — intervention group
Group type: COMPARATOR
Intervention: Preexisting antibodies
Number of subjects: 20
Study 6514179 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 0
Study 6514179 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (8 mg)
Number of subjects: 0
Study 6514179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31145207 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical insulin (TI) 1 unit/drop 4 times per day for 4 weeks
Number of subjects: 160
Study 31145207 — intervention group
Group type: COMPARATOR
Intervention: Standard artificial tears (SAT)
Number of subjects: 160
Study 31145207 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical insulin (TI)
Number of subjects: 160
Study 30522397 — intervention group
Group type: EXPERIMENTAL
Intervention: Homemade street foods (e.g., fried cakes, stewed meat/fish/liver dishes)
Number of subjects: 968
Study 30522397 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamburgers
Number of subjects: 968
Study 30522397 — intervention group
Group type: EXPERIMENTAL
Intervention: Stewed liver dishes
Number of subjects: 968
Study 27742752 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-controlled vocal exercise
Number of subjects: 199
Study 27742752 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 199
Study 26436491 — intervention group
Group type: EXPERIMENTAL
Intervention: TORS alone
Number of subjects: 80
Study 26436491 — intervention group
Group type: EXPERIMENTAL
Intervention: TORS plus adjuvant therapy
Number of subjects: 80
Study 26436491 — intervention group
Group type: COMPARATOR
Intervention: TORS group
Number of subjects: 80
Study 25152982 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 weeks PEG‐RBV therapy (group B)
Number of subjects: 166
Study 25152982 — intervention group
Group type: COMPARATOR
Intervention: 48 weeks PEG‐RBV therapy (group A)
Number of subjects: 166
Study 21112054 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 400 μg 3 hours before MVA
Number of subjects: 600
Study 21112054 — intervention group
Group type: COMPARATOR
Intervention: Vaginal placebo 3 hours before MVA
Number of subjects: 600
Study 21112054 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 400 μg 3 hours before EVA
Number of subjects: 600
Study 21112054 — intervention group
Group type: COMPARATOR
Intervention: Vaginal placebo 3 hours before EVA
Number of subjects: 600
Study 19158210 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation of 125 mg FeSO4 daily from 10 weeks to 9 months postpartum (IDA-Fe)
Number of subjects: 95
Study 19158210 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (IDA-PL)
Number of subjects: 95
Study 19158210 — intervention group
Group type: COMPARATOR
Intervention: Control group (iron-sufficient mothers)
Number of subjects: 95
Study 17479608 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 55 microg
Number of subjects: 641
Study 17479608 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 110 microg
Number of subjects: 641
Study 17479608 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 220 microg
Number of subjects: 641
Study 17479608 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 440 microg
Number of subjects: 641
Study 17479608 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 110 microg and 440 microg
Number of subjects: 641
Study 17479608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 641
Study 15184207 — intervention group
Group type: EXPERIMENTAL
Intervention: FP Accuhaler 2000 microg/day
Number of subjects: 21
Study 15184207 — intervention group
Group type: EXPERIMENTAL
Intervention: FP Accuhaler 1000 microg/day
Number of subjects: 21
Study 15184207 — intervention group
Group type: EXPERIMENTAL
Intervention: MF Twisthaler 1600 microg/day
Number of subjects: 21
Study 15184207 — intervention group
Group type: EXPERIMENTAL
Intervention: MF Twisthaler 800 microg/day
Number of subjects: 21
Study 19397013 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-guided education program, facilitated telephone communication, and regularly scheduled follow-up visits with an internist (Intervention group, n = 100)
Number of subjects: 200
Study 19397013 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group, n = 100)
Number of subjects: 200
Study 9512223 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cortisol concentration in follicular fluid from fertilized oocytes in 'low responder' patients (group 1)
Number of subjects: 35
Study 9512223 — intervention group
Group type: COMPARATOR
Intervention: Total cortisol concentration in follicular fluid from fertilized oocytes in 'good responder' patients (group 2)
Number of subjects: 35
Study 9512223 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cortisol concentrations in follicular fluid of unfertilized oocytes or empty follicles
Number of subjects: 35
Study 9512223 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cortisol concentrations in follicular fluid
Number of subjects: 35
Study 8040955 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate surgery
Number of subjects: 1350
Study 8040955 — intervention group
Group type: COMPARATOR
Intervention: Selective surgery (follow-up with ultrasonography or CT every 6 months)
Number of subjects: 1350
Study 2725369 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for lay subjects
Number of subjects: 0
Study 2725369 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for medical students
Number of subjects: 0
Study 2725369 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for teaching staff
Number of subjects: 0
Study 2725369 — intervention group
Group type: COMPARATOR
Intervention: No training for teaching staff
Number of subjects: 0
Study 2725369 — intervention group
Group type: COMPARATOR
Intervention: No training for medical students
Number of subjects: 0
Study 2725369 — intervention group
Group type: COMPARATOR
Intervention: No training for lay subjects
Number of subjects: 0
Study 1130879 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraluminal 5 FU (30mg/kg) with intravenous 5 FU (10mg/kg) on the first two postoperative days and 5 subsequent postoperative courses of oral 5 FU (90 mg/kg in each 18 day course) over one year period.
Number of subjects: 156
Study 1130879 — intervention group
Group type: COMPARATOR
Intervention: Intraluminal control (Saline) group.
Number of subjects: 156
Study 30925507 — intervention group
Group type: EXPERIMENTAL
Intervention: Early parent interaction program
Number of subjects: 151
Study 30925507 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 151
Study 29065960 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 42
Study 29065960 — intervention group
Group type: COMPARATOR
Intervention: Mandibular Advancement Device (MAD)
Number of subjects: 42
Study 29065960 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CPAP and MAD
Number of subjects: 42
Study 26501118 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication treatment (lansoprazole, clarithromycin, metronidazole)
Number of subjects: 3038
Study 26501118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3038
Study 23596810 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean red ginseng extract (1500 mg)
Number of subjects: 40
Study 23596810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21146763 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced focus on physical appearance (Appearance)
Number of subjects: 203
Study 21146763 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined focus on appearance and health (Combined)
Number of subjects: 203
Study 21146763 — intervention group
Group type: COMPARATOR
Intervention: Standard behavioral intervention
Number of subjects: 203
Study 21146763 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction measures (Multidimensional Body‐Self Relations Questionnaire, Medical Outcomes Study Short Form‐36)
Number of subjects: 203
Study 18585631 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin administration after each BCG instillation
Number of subjects: 0
Study 18585631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16864926 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonist (CAA) - verapamil
Number of subjects: 29
Study 16864926 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker (BB) - bisoprolol, atenolol or metoprolol
Number of subjects: 29
Study 16864926 — intervention group
Group type: COMPARATOR
Intervention: Digitalis (control)
Number of subjects: 29
Study 12888781 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5 mg)
Number of subjects: 0
Study 12888781 — intervention group
Group type: COMPARATOR
Intervention: Cyproheptadine (4 mg)
Number of subjects: 0
Study 11156042 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA barrier in combination with DFDBA
Number of subjects: 30
Study 11156042 — intervention group
Group type: COMPARATOR
Intervention: PLA barrier alone
Number of subjects: 30
Study 9196381 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA (3 mg/kg administered i.v. over 5 minutes)
Number of subjects: 10
Study 10183117 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider expertise
Number of subjects: 0
Study 10183117 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient care
Number of subjects: 0
Study 10183117 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct experience
Number of subjects: 0
Study 3085612 — intervention group
Group type: EXPERIMENTAL
Intervention: Thallium-201 myocardial scintigraphy
Number of subjects: 32
Study 3085612 — intervention group
Group type: COMPARATOR
Intervention: Other non-invasive investigations
Number of subjects: 32
Study 31093939 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy interns
Number of subjects: 218
Study 31093939 — intervention group
Group type: COMPARATOR
Intervention: Pharmacists
Number of subjects: 218
Study 31093939 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses to ethical vignette scenarios
Number of subjects: 218
Study 31093939 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to potential privacy breaches
Number of subjects: 218
Study 29605319 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxy-l-tryptophan (5-HTP) 1 mg/kg
Number of subjects: 31
Study 29605319 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxy-l-tryptophan (5-HTP) with negative DCAD diet
Number of subjects: 31
Study 29605319 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative DCAD diet
Number of subjects: 31
Study 29605319 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 31
Study 26944262 — intervention group
Group type: EXPERIMENTAL
Intervention: Single fraction of 28Gy
Number of subjects: 84
Study 26944262 — intervention group
Group type: COMPARATOR
Intervention: 48Gy in four fractions of SABR
Number of subjects: 84
Study 24579923 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF
Number of subjects: 102
Study 24579923 — intervention group
Group type: COMPARATOR
Intervention: IUI
Number of subjects: 102
Study 23098865 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg daily for 10 days
Number of subjects: 57
Study 23098865 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 57
Study 23098865 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 57
Study 23098865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 19443519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ismigen (one capsule daily for the first 10 days of three consecutive months)
Number of subjects: 63
Study 17264722 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 0.5 mg/kg
Number of subjects: 80
Study 17264722 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 4.0 mg/kg
Number of subjects: 80
Study 17264722 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 1.0 mg/kg
Number of subjects: 80
Study 17264722 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 8.0 mg/kg
Number of subjects: 80
Study 17264722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 15479362 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg
Number of subjects: 27
Study 15479362 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg
Number of subjects: 27
Study 15479362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 11966949 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg acutely, 12.5 mg daily for 7 days)
Number of subjects: 36
Study 11966949 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (80 mg acutely, 80 mg daily for 7 days)
Number of subjects: 36
Study 11966949 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 36
Study 11966949 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 36
Study 9846467 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin eardrops plus aspiration in the clinic, n = 40 (47 ears)
Number of subjects: 80
Study 9846467 — intervention group
Group type: COMPARATOR
Intervention: Self-administered ciprofloxacin eardrops at home, n = 40 (48 ears)
Number of subjects: 80
Study 8134058 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental clinic high-risk patients
Number of subjects: 290
Study 8134058 — intervention group
Group type: COMPARATOR
Intervention: Control clinic high-risk patients
Number of subjects: 290
Study 2598571 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin administered alone (750 mg) as control treatment
Number of subjects: 0
Study 2598571 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin administered 5 to 10 minutes after antacid (30 ml)
Number of subjects: 0
Study 2598571 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin administered 2 hours after antacid (30 ml)
Number of subjects: 0
Study 2598571 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin administered 4 hours after antacid (30 ml)
Number of subjects: 0
Study 2598571 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin administered 6 hours after antacid (30 ml)
Number of subjects: 0
Study 2598571 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin administered 2 hours after ranitidine (200 mg)
Number of subjects: 0
Study 241181 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent dosage schedules of antipsychotic preparations with reduced antiparkinsonic agents
Number of subjects: 300
Study 241181 — intervention group
Group type: COMPARATOR
Intervention: High doses of chlorpromazine
Number of subjects: 300
Study 31386199 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 623
Study 31386199 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 623
Study 28804124 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (IM) at 400 mg/day
Number of subjects: 1551
Study 28804124 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-CML determinants
Number of subjects: 1551
Study 26441006 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone or flupenthixol long acting injection
Number of subjects: 22
Study 26441006 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 22